Altimmune, Inc. (ALT)
2.735
+0.02
(+0.92%)
USD |
NASDAQ |
Jun 08, 16:00
2.74
0.00 (0.00%)
After-Hours: 20:00
Altimmune Shareholders Equity (Quarterly) : 283.99M for March 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Agenus, Inc. | -221.22M |
| Amgen, Inc. | 9.19B |
| Halozyme Therapeutics, Inc. | 219.64M |
| Protalix Biotherapeutics, Inc. | 67.23M |
| Humacyte, Inc. | 11.62M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 335.63M |
| Total Liabilities (Quarterly) | 51.64M |
| Debt to Equity Ratio | 0.1262 |
| Current Ratio | 29.54 |
| Net Debt Paydown Yield | -1.70% |